Lyell Immunopharma, Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Find out what a historical investment in Lyell Immunopharma, Inc would be worth today using our LYEL stock calculator.
$540.22M
-
0.00%
7.16K
$25.50
$24.92
$25.38
$25.59
$7.65
Ready to start your investing journey with Stake?
Open an accountLYEL FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in LYEL
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in LYEL
on Stake
Buy LYEL from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of LYEL from only US$10 with fractional shares
